• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Evotec SE (Amendment)

    2/2/23 1:24:31 PM ET
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVO alert in real time by email
    SC 13G/A 1 d439809dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No.1)*

     

     

    Evotec SE

    (Name of Issuer)

     

     

    Ordinary Shares, no par value per share

    (Title of Class of Securities)

    30050E105

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No.: 30050E105

     

      1.    

      Name of Reporting Person:

     

      Novo Holdings A/S

      2.  

      Check the Appropriate Box if a Member of Group (See Instructions):

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only:

     

      4.  

      Citizenship or Place of Organization:

     

      Denmark

    Number of

    Shares

     Beneficially 

    Owned By

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power:

     

      17,444,807

       6.  

      Shared Voting Power:

     

      0

       7.  

      Sole Dispositive Power:

     

      17,444,807

       8.  

      Shared Dispositive Power:

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person:

     

      17,444,807

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares:

     

      ☐

    11.  

      Percent of Class Represented By Amount In Row (9):

     

      9.8 %(1)

    12.  

      Type of Reporting Person:

     

      CO

     

    (1)

    Based upon 176,952,653 Ordinary Shares of the Issuer outstanding as of September 30, 2022, reported in the Issuer’s Form 6-K filed with the Securities and Exchange Commission (“SEC”) on November 9, 2022.

     

    2


    Item 1.    (a)

    Name of Issuer:

    Evotec SE

     

                    (b)

    Address of Issuer’s Principal Executive Offices:

    Essener Bogen 7

    22419 Hamburg

    Germany

     

    Item 2.    (a)

    Name of Person Filing:

    Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

     

                    (b)

    Address or Principal Business Office or, if none, Residence:

    Tuborg Havnevej 19

    2900 Hellerup, Denmark

     

                    (c)

    Citizenship or Place of Organization:

    Denmark

     

                    (d)

    Title of Class of Securities:

    Ordinary Shares

     

                    (e)

    CUSIP Number:

    30050E105

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

     

    Item 4.

    Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

       Amount beneficially owned:      17,444,807        (1 ) 

    (b)

       Percent of class:      9.8 %       (2 ) 

    (c)

       Number of shares as to which such person has:      
       (i) Sole power to vote or to direct the vote:      17,444,807        (1 ) 
       (ii) Shared power to vote or to direct the vote:      0   
       (iii) Sole power to dispose or to direct the disposition of:      17,444,807        (1 ) 
       (iv) Shared power to dispose or to direct the disposition of:      0     

     

    (1)

    Novo Holdings A/S has the sole power to vote and dispose of the shares, and no individual or other entity is deemed to hold any beneficial ownership in the shares.

    (2)

    Based upon 176,952,653 Ordinary Shares of the Issuer outstanding as of September 30, 2022, reported in the Issuer’s 6-K filed with the SEC on November 9, 2022.

     

    3


    Item 5.

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6.

    Ownership of More Than Five Percent on Behalf of Another Person:

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group:

    Not applicable.

     

    Item 10.

    Certifications:

    Not applicable.

     

    4


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 2, 2023     Novo Holdings A/S
       

    /s/ Barbara Fiorini Due

        By:   Barbara Fiorini Due
        Its:   General Counsel, Finance & Operations
    Get the next $EVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EVO

    DatePrice TargetRatingAnalyst
    4/24/2025Sell → Hold
    Deutsche Bank
    10/7/2024Buy → Hold
    Jefferies
    8/8/2024Hold → Sell
    Deutsche Bank
    7/29/2024$15.00 → $6.00Overweight → Equal-Weight
    Morgan Stanley
    7/11/2024Buy → Hold
    Deutsche Bank
    4/12/2024Hold → Buy
    Deutsche Bank
    1/18/2024Sector Perform → Outperform
    RBC Capital Mkts
    6/23/2023$12.00 → $16.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Evotec SE upgraded by Deutsche Bank

      Deutsche Bank upgraded Evotec SE from Sell to Hold

      4/24/25 7:18:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Jefferies

      Jefferies downgraded Evotec SE from Buy to Hold

      10/7/24 7:52:16 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE downgraded by Deutsche Bank

      Deutsche Bank downgraded Evotec SE from Hold to Sell

      8/8/24 8:58:18 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

      Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaboration to develop first-in-class therapeutic antibodies to treat asthma and idiopathic pulmonary fibrosis HAMBURG, GERMANY / ACCESS Newswire / January 22, 2025 / Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat l

      1/22/25 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

      Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseasesLAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions HAMBURG, DE / ACCESSWIRE / December 11, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((SDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) announced that its translational drug discovery accelerator with Novo Nordisk, LAB eN², which aims to nurture early research from acade

      12/11/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec Announces Change in Management Board

      Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024Distribution of responsibilities internally HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Managemen

      11/29/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Leadership Updates

    Live Leadership Updates

    See more
    • Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell Therapies

      Novo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies HAMBURG, GERMANY / ACCESSWIRE / September 26, 2024 / Evotec SE ((Frankfurt Stock Exchange:EVT, SDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) announced today that Evotec has entered a technology development partnership with Novo Nordisk in cell therapy.Both Evotec and Novo Nordisk have significant expertise and a strategic focus to support stem cell-based therapies. In order to provide next-generation off-the-shelf cell therapy products for clinical development and possible commercialisation thereafter, the companies will collaborate on developm

      9/26/24 2:00:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE: Results of the Annual General Meeting 2024

      Most agenda items adopted with great majorityAnnual General Meeting 2024 elects Dr Duncan McHale and Wesley Wheeler to the Supervisory Board, replacing Dr Elaine Sullivan and Dr Mario PolywkaHAMBURG, GERMANY / ACCESSWIRE / June 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, OTC:EVOTF)(NASDAQ:EVO) today announced that its shareholders approved most of the proposals the Company's Management put to vote at the Company's Annual General Meeting 2024 with great majority.Under the topic "Together for Medicines that Matter - Weg zum Neustart", the Chairperson of the Supervisory Board of Evotec SE, Prof. Dr Iris Löw-Friedrich, Chief Business Officer Dr Matthias Evers and Chief Fina

      6/10/24 12:15:00 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE appoints Dr Christian Wojczewski as Chief Executive Officer

      HAMBURG, GERMANY / ACCESSWIRE / April 23, 2024 / The Supervisory Board of Evotec SE ((Frankfurt Stock Exchange: EVT, MDAX/TecDAX, OTC:EVOTF, NASDAQ:EVO) has appointed Dr Christian Wojczewski as the Company's new Chief Executive Officer ("CEO"), effective 01 July 2024. The election was unanimous and is the result of an extensive selection process that began in January.Dr Mario Polywka, who has led Evotec as Interim CEO since 03 January 2024, will retire from his position at the end of June and will also not seek re-election for his dormant Supervisory Board mandate, which expires with the 2024 Annual General Meeting.Dr Christian Wojczewski holds a degree in chemistry and has over 20 years of

      4/23/24 3:00:00 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Evotec SE

      SC 13D - Evotec SE (0001412558) (Subject)

      11/8/24 9:43:55 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evotec SE (Amendment)

      SC 13G/A - Evotec SE (0001412558) (Subject)

      2/14/24 4:55:09 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Evotec SE (Amendment)

      SC 13G/A - Evotec SE (0001412558) (Subject)

      2/2/23 1:24:31 PM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    Financials

    Live finance-specific insights

    See more
    • Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

      Guidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditionsRobust growth of Just - Evotec Biologics driven by roll out of projects together with Sandoz and progress of discovery partnershipsSuccessful extensions & expansions with BMS and Novo Nordisk; new collaboration with Pfizer to advance cutting-edge therapeutic solutionsPriority reset on track to deliver annualised adj. EBITDA improvement of over € 40 m and strategic review initiated HAMBURG, GERMANY / ACCESSWIRE / November 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) today announced its financial results and corporate upda

      11/6/24 1:20:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024

      HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)((MDAX/TecDAX, TRQX:EVTd)(NASDAQ:EVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.The Company is going to hold a conference call to discuss 9-months results as well as to provide an overview on the ongoing priority reset and the strategic review process. The conference call will be held in English.Webcast detailsDate: Wednesday, 06 November 2024Time: 2.00 pm CET (01.00 pm GMT, 08.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our we

      10/30/24 3:30:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

      Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024Strong progress of Just - Evotec Biologics with H1 2024 revenues increase of 50% year-on-year; capacity ramp-up for J.POD in Toulouse has been acceleratedChallenging market environment and high fixed cost base led to weaker profitability. Priority reset towards profitable growth gaining momentumDr Christian Wojczewski, CEO as of 1 July, is announcing an accelerated transformation programme for the company, building on the core innovation strengths of Evotec HAMBURG, G

      8/14/24 1:30:00 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EVO
    SEC Filings

    See more
    • SEC Form 6-K filed by Evotec SE

      6-K - Evotec SE (0001412558) (Filer)

      5/6/25 6:00:17 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Evotec SE

      20-F - Evotec SE (0001412558) (Filer)

      4/17/25 6:05:32 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Evotec SE

      6-K - Evotec SE (0001412558) (Filer)

      4/17/25 6:02:39 AM ET
      $EVO
      Biotechnology: Pharmaceutical Preparations
      Health Care